INTRODUCTION
Current anti-retroviral combination drug therapy (highly active anti-retroviral therapy, HAART) reduces morbidity and mortality in human immunodeficiency virus type 1 (HIV-1)-infected individuals (reviewed by Gazzard, 1999; Shafer & Vuitton, 1999) . However, the toxicity of antiretroviral drugs, compliance with the life-long regimen and the evolution of antiretroviral resistance in the face of drug pressure illustrate the limitations of this approach (Shafer & Vuitton, 1999) . Alternative strategies to inhibit virus replication, either alone or in combination with those currently practised, are desirable (Mautino & Morgan, 2002) .
One adjunctive strategy explored here involves the use of a ribozyme. Ribozymes are catalytic RNA molecules that can be engineered to cleave specifically and effectively destroy a given target RNA (Cech, 1987) , presenting an attractive method for reducing viral load in HIV-1 infection (reviewed by Rossi, 2000) . A limiting step in the current use of ribozymes, however, is their delivery to virus-infected cells. Due to safety concerns, emphasis on therapeutic gene delivery has relied on the development of replication-defective, recombinant retroviral vectors (Barinaga, 1994; Miller & Wolgamot, 1997) . Successful gene transfer to human T cells, stem cells, dendritic cells and bone marrow has been achieved, with expression of the marker gene ranging from weeks to 36 months (Bauer et al., 1997; Leavitt et al., 1994; Mangeot et al., 2002; Yu et al., 1995) . The delivery of gene therapy vectors and subsequent gene transfer have involved direct transduction of the target cells with the desired vector (Buchschacher & Wong-Staal, 2000) . This method has not proved practical as it involves ex vivo transductions, with the infusion of the transduced cells back into the infected individual.
An alternative strategy for a gene therapy vector delivery system involves revising the current paradigm and using conditional-replicating or mobilizable vectors, with the cells already infected for vector propagation. However, the use of such vectors could be expected to be limited by any anti-viral genes within the vector (Klimatcheva et al., 2001) . None the less, it has previously been shown that the packaging of vector RNA creates competition for encapsidation of viral RNA, reducing the amount of wildtype virions roughly sixfold, leading to reduced particle infectivity and mobilization of vector to target cells (Corbeau & Wong-Staal, 1998; Evans & Garcia, 2000) . Moreover, when the vectors express ribozymes targeting HIV-1 RNA, a significantly higher competitive advantage for the vector RNA packaging into virions over the wildtype viral RNA is observed (Dropulic & Pitha, 1996) .
The use of vectors that are replication-defective unless co-infected into cells with replication-competent virus may provide an avenue of antiretroviral vector delivery to viral reservoirs that could be tested in the simian immunodeficiency virus (SIV)/rhesus macaque model. The formation of such replication-defective particles has been shown to be contingent not only on a viable packaging cell line, but also on the 59-and 39LTR from HIV or SIV (HIV Tat can transactivate vectors containing the SIV LTR; Arya, 1988) , the Y packaging signal and the Revresponsive element (RRE) site (Aronoff & Linial, 1991; Garzino-Demo & Arya, 1995; Geigenmuller & Linial, 1996; Joshi et al., 1997; Parolin et al., 1996) . A mobilizable vector that expresses anti-viral genes, such as a ribozyme, represents a shift in objective from protecting uninfected cells to potentially reducing overall virus propagation in already infected cells (Klimatcheva et al., 2001; Mautino et al., 2001; Mautino, 2002) .
The data presented here suggest that an SIV-based vector containing an anti-SIV pol ribozyme has an antiretroviral activity that is the result of the ribozyme cutting transcripts containing the SIV pol gene encoding the reverse transcriptase (RT). The vector tested here was able to exploit the intracellular viral machinery of the SIV-infected cells and propagate in a fashion similar to the wild-type virus. Such a mobilization-competent anti-SIV vector relies on the viral proteins expressed within the virus-infected cells to drive the expression of the anti-SIV pol ribozyme, as well as to propagate and package the vector. Importantly, data presented here are, to our knowledge, the first characterization of a mobilization-competent SIV-based vector containing a ribozyme targeting the wild-type virus.
METHODS
Vectors. The vectors used in this study were derived from SIVmac239D3, a two-plasmid system; the plasmid 59p53Dvpr contains the 59 half of SIV (9411 bp) and 39p239-39DnefDU3 contains the 39 half (6789 bp) (Desrosiers et al., 1998; Gibbs et al., 1994; Regier & Desrosiers, 1990) . To use the SstI site, which lies 59 of the deleted nef, for the cloning of the anti-SIV pol ribozyme, the SstI site in the flanking genomic DNA was first removed. Briefly, the 39LTR (minus flanking genomic DNA) was PCR-amplified from 39p239-39DnefDU3 with the primers 59 SstI (59-CCCCAGGAGGAT-TAGACAAGGGCTTGAGCTCACT-39) and 39 EcoRI (59-GCGGAA-TTCTGCTAGGGATTTTCCTGCTTCGG-39) under the following conditions: 1 cycle of 95 uC for 8 min; 30 cycles of 95 uC for 45 s, 55 uC for 45 s and 72 uC for 45 s; followed by 1 cycle of 72 uC for 10 min. Unless otherwise stated, all PCRs were performed in a total volume of 50 ml, comprising 5 ml 106 PCR buffer (50 mM KCl, 10 mM Tris/HCl, pH 7?5, 25 mM MgCl 2 ), 8 ml dNTP mix (1?25 mM solution), 2 ml each primer (20 pmol ml 21 ) for a total of 40 pmol per reaction, 0?25 ml Taq DNA polymerase (5 U ml 21 ), 31?75 ml sterile DNase-free water and 1 ml of sample. The PCRamplified 39LTR was SstI and EcoRI digested along with the similarly digested 39 p239-39DnefDU3, which was 0?8 % agarose gel purified to remove the 39LTR and then ligated with the resultant PCR-amplified 39LTR to produce 39p239-39DnefDU3Sst.
The 59LTR was amplified by PCR with the primers 59 LTR-XhoI (59-GCGGCATGCGCATGCACATTTTAAAGGCTTTTGCTAAATA-TAGCC-39) and 39 LTR-SphI (59-GCGCTCGAGTCTCCCACTCTA-TCTTATTACCCCTTCCTGGATA-39), using the 59p53Dvpr plasmid containing the 59 half of SIV as the template (Desrosiers et al., 1998; Gibbs et al., 1994; Regier & Desrosiers, 1990) . One microgram of the PCR-amplified 59LTR was XhoI/SphI digested. The 39p239-39DnefDU3Sst plasmid was digested with XhoI (10-60 U ml 21 ) and SphI (1-4 U ml 21 ) (Stratagene) and ligated to the similarly treated PCR-amplified 59LTR. To confirm that the 59LTR was correctly cloned into the vector, sequencing was carried out using the primers 39 LTR-XhoI and 39 SIV env (59-GGGCTATACAAGAACTAGTCT-CATTGACCATGTCTAC-39).
Anti-SIV pol ribozyme. The design of the SIV-specific anti-pol hammerhead ribozyme (anti-SIV-RT) followed previously established protocols in ribozyme design (Akhtar et al., 1995; Amarzguioui & Prydz, 1998; James & Gibson, 1998; Marschall et al., 1994; Regier & Desrosiers, 1990) (Fig. 1d) . The anti-SIV-RT ribozyme was synthesized by PCR amplification using the ribozyme template 59-AAGAGTTCCTTTCTGATGAGTCCGTGAGGACGAAACTGTA-AAACTA-39 with the primers 59-Sense RT (59-GCGGAGCTCA-AGAGTTCCTTTCTGATGAGTC-39) and 39-Antisense RT (59-GC-GGAGCTCTAGTTTTACAGTTTCGTCCT-39) (Protein Structure Laboratory, University of California Davis). Both the sense and antisense ribozyme primers contained internal SstI restriction sites.
Plasmid p5T (Fig. 1a) and PCR-amplified anti-SIV-RT ribozyme were digested with SstI and ligated. The SstI ligation site within p5T was 59 of the 184 bp deletion in nef at nt 9250-9434, and both sense and antisense orientations of ribozymes were obtained following transformation, as detected by direct sequencing of PCR products generated using the SIV-specific primer 59 SIV env (59-GGGAGA-CTTATGGGAGACTCTTAGGAGAGG-39) and either the anti-SIV-RT 59-Sense or 39-Antisense RT ribozyme primers. Vectors containing the anti-SIV-RT ribozyme in sense (p4T) and antisense (p1T) orientations were selected ( Fig. 1b and c, respectively).
Characterization of mobilized vector from SIV-infected cultures.
CEMx174 cells (5610 4 ) were infected with SIVmac251 (m.o.i. of 6 for 2 h), washed with PBS and added to 1?0610 7 CEMx174 cells to create a culture containing 0?5 % infected cells. Twenty-four hours later, the 0?5 % infected cultures were DEAE-dextran transfected (Milman & Herzberg, 1981; Naidu et al., 1988) in duplicate with 5?0 mg of the respective vectors ( Fig. 1a-c) . Mock cultures were not transfected with vector. These cultures were washed with PBS and split 24 h post-transfection into quadruplicate wells and incubated at 37 uC, 5 % CO 2 and the medium changed every 3-4 days.
Virions from the SIVmac251-infected vector-transfected culture were isolated from filter-sterilized (0?45 mM) supernatants by centrifugation (SS34 rotor, Sorvall RC5 centrifuge, 20 000 g at 4 uC for 2 h). RNA was extracted from the pelleted virus (Qiagen viral extraction kit) and quantified by spectrophotometer (Pharmacia Biotech, Gene Quant II). One microgram RNase-free DNase I-treated (4 h at 37 uC) viral RNA in 10 ml RNase-free water served as the template for the RT reaction. The 20 ml RT reaction contained 2 ml SIV primer cocktail with primers specific for pol (59-GAATACCACACCCTGCAGGAC-TAGC-39), the 39LTR (59-CTCCCACTCTATCTTATTACCCCTTC-CTGGATAAAAGACAGC-39) and the 59 SIV env (20 pmol ml 21 of each primer), 0?5 ml AMV RT (5 U ml 21 ), 1 ml 1?25 mM dNTPs, 4 ml RT buffer (100 mM Tris/HCl, pH 9?0 at 25 uC, 500 mM KCl, 15 mM MgCl 2 , 1 % Triton X-100), 0?5 ml RNaseOUT (20-40 U ml 21 ), 1 ml DTT, 1 ml RNase-free water and 10 ml RNA. The viral RNA was added to this and reverse transcription was carried out at 42 uC, then inactivated for 10 min at 95 uC. The presence of vector cDNA was determined by PCR using the 59 SIV env primer and either the 59-Sense RT (as a 39 primer) or the 39-Antisense RT ribozyme-specific primer, depending on the orientation of the ribozyme within the vector. The products were sequenced for final confirmation. Supernatants shown to contain the anti-SIV-RT ribozyme vectors packaged by wild-type SIVmac251 were filter-sterilized (0?2 mm) and 100 ml was serially passaged in 1610 7 uninfected CEMx174 cells. Viral RNA from the supernatants of the serially passaged CEMx174 cultures was also RT-PCR amplified and sequenced to confirm the presence of the anti-SIV-RT ribozyme.
Characterization of anti-SIV-RT ribozyme action by HPLC.
Cellular RNA was isolated (RNeasy isolation kit; Qiagen) and RT-PCR-amplified, using virus primers described above. PCR was carried out, based on earlier work (Dropulic et al., 1992) , using various pol-specific primers: primer A (59-GGTCACCAGCCATC-TTCCAATAC-39), primer B (59-AAACTACCCTGTCATGTTCCA-39) and primer C (59-GTAGAAAACCCTATGCTATTCAAG-39) on either side of the ribozyme-specific cut site of the pol gene (see Fig. 4a ). As an internal control, the 59 Nef (59-GGCTCTCTGCG-ACCCTACAGAGGATTCGAGAAGTCCT-39) and 39 Nef (59-TAAA-TCCCTTCCAGTCCCCCCTTTTCTT-39) primers were also added to the PCR cocktail. The conditions for PCR amplification of the templates were 1 cycle of 95 uC for 8 min; 30 cycles of 95 uC for 45 s, 55 uC for 45 s, 72 uC for 45 s; followed by 1 cycle of 72 uC for 8 min. These parameters allowed culmination of the amplification in the exponential phase. The Varion ProStar 340 (UV-Vis Detector), 210/215 (Solvent Delivery Module) denaturing highpressure liquid chromatography (DHPLC) system was used to quantify ribozyme cutting of pol RNA (specifically the RT gene) in infected cells. The profile used to measure the amplified PCR products contained peaks at 4?139 min and 5?25 min, times that coincided with the expected size based on a wX174 Hae molecular mass marker. The products were measured as counts s 21 and the integrated area under the curve was calculated and compared.
Limiting-dilution PCR. Genomic DNA was isolated (Qiagen genomic DNA isolation kit) at various time points from CEMx174 cells that had been exposed to 100 ml filter-sterilized (0?2 mm) serially passaged supernatants. Viral RNA from the same CEMx174 cultures at various time points following infection with the filtersterilized mobilization-competent-vector-containing supernatants was also isolated and reverse-transcribed as described above. The resultant viral cDNA and genomic DNA were then serially diluted 10-fold along with the starting vector plasmid p4T or SIVmac239 plasmid (p239) and PCR-amplified. Vector-specific primers used in this assay were either anti-SIV-RT sense or anti-sense paired with either the SIV-specific 59 Nef or 39 Nef. To calculate the amount of SIVmac251 (non-vector) viral RNA, SIV-specific 59 Tat (59-G-CGGCATGCATGGAGACACCCTTGAGGGAGCAGGAGAA-39) and 39 Tat (59-GCGGCATGCTTCTAGAGGGCGGTATAG-39) primers were used.
The limiting-dilution end-point PCR (Sykes et al., 1992) was carried out under the following conditions: 1 cycle of 95 uC for 8 min; 25 cycles of 95 uC for 45 s, 55 uC for 45 s and 72 uC for 45 s; followed by 1 cycle of 72 uC for 8 min. The products of the limiting-dilution PCR or RT-PCR (RT step as described previously) (12 ml) were run on a 3 % agarose gel and compared with end-points of the known plasmid, either p4T or p239. The final viral or vector copy number ml 21 was calculated from standard plasmid (p4T or p239) end-point copies ml 21 using the equation: C=(X*6?022610
23
)/(660*Y*1?0610 9 ) where C=number of copies, X=concentration of DNA/cDNA (mg ml 21 ) and Y=vector or virus base pair numbers.
SIV p27 ELISA. Two hundred microlitres of each transfected and SIVmac251-infected CEMx174 cell culture supernatant and SIVmac251-infected rhesus macaque sera, titred and used as standards (a gift from Joanne Higgins, University of California Davis Center for Comparative Medicine), were placed in each well of a 96-well plate coated with canine anti-SIV IgG-biotin (Lohman et al., 1991) and incubated for 1 h at 37 uC. The plates were washed three times with ELISA wash buffer (0?15 M NaCl, 0?05 % Tween 20 in distilled water) and incubated for 1 h at 37 uC with rabbit anti-SIV-p27 serum (Lohman et al., 1991) diluted 1 : 20 000. The plates On: Mon, 14 Jan 2019 11:52:34
were washed three times with ELISA wash buffer and incubated for 20 min with goat anti-rabbit horseradish peroxidase-labelled IgG (1 : 5000 dilution). The plates were washed three times in ELISA wash buffer and developed using the substrate 3,39,5,59-tetramethyl benzidine in the presence of H 2 O 2 and citric acid, as described previously (Lohman et al., 1991) . All absorbance values were derived from readings on a Bio-Rad plate reader at 450 nm with a reference wavelength of 570 nm using Microplate Manager 2.2 software (Macintosh).
RESULTS
Vectors p5T (no ribozyme), p4T (containing the ribozyme anti-SIV-RT in the sense orientation) and p1T (containing the ribozyme anti-SIV-RT in the antisense orientation) (Fig. 1a-c, respectively) containing the minimal requirements for expression and mobilization -a functional 59-and 39LTR, a Y packaging signal and the RRE site (Barinaga, 1994; Kim et al., 1998) -were transfected into a mixture of CEMx174 cells of which 0?5 % were infected with SIVmac251. This mixture of cells was used to simulate, in vitro, a spreading retroviral infection. Transfected cultures were monitored for SIV p27 expression by ELISA and for cell viability by trypan blue staining. Ribozymetransfected cultures did not differ from controls with regard to cell viability. From day 7 to 14, the p4T-transfected (sense) SIVmac251-infected cultures produced lower levels of SIV p27 than controls. These cells expressed 83 and 86 % p27 relative to SIVmac251-infected cells transfected with p1T, 82 and 83 % p27 relative to infected cells transfected with p5T, and 84?4 and 86?4 % p27 relative to mocktransfected infected cells on days 7 and 14 post-transfection, respectively (Fig. 2a) .
To assess vector mobilization, 100 ml of filter-sterilized supernatants from the above cultures from day 14 posttransfection were passaged onto fresh uninfected CEMx174 cells. While a trend towards reduced SIV p27 expression initially appeared conserved in the cultures treated with passaged supernatants, the differences were not statistically significant (p27 expression in cells transfected with p4T relative to mock-transfected cells was 69 % on day 2, 100 % on day 5, 90 % on day 11 and 86 % on day 14; Fig. 2b ). To determine whether the ribozyme-containing vector was present in the passaged supernatants, we isolated and amplified viral RNA from supernatants at day 21 posttransfection. RT-PCR with the 59 SIV env primer and either the 59 or the 39 anti-SIV-RT-specific primer showed the presence of the anti-SIV-RT ribozyme-containing vector in the culture supernatants (Fig. 3a) . The competency of the vector to mobilize and subsequently transduce new cells was determined using the same PCR primers and genomic DNA, as well as supernatants from the passaged supernatant-infected CEMx174 cells. At day 2 post-serial passage, there were detectable levels of the anti-SIV-RT ribozyme in the genomic DNA of the fresh supernatantexposed CEMx174 cells (Fig. 3b) .
Next DHPLC was employed, based on previous methodologies (Dropulic et al., 1992) , in an attempt to determine whether or not the reduced SIV p27 levels seen posttransfection were a result of anti-SIV-RT ribozyme cutting the polymerase (pol)-containing transcript of SIVmac251. Cellular RNA from transfected cell cultures was DNase I-treated and RT-PCR-amplified for SIV RNA and the respective ratios of cut versus uncut RNA products were compared by DHPLC (Fig. 4a) . The p4T sense anti-SIV-RT vector-transfected cultures contained a significant increase in the ratio of cut to uncut pol transcripts from day 4 to day 9, as well as a reduction in the overall percentage of nef transcripts, a trend that was not observed in the p1T-treated samples containing the ribozyme in the antisense orientation, nor in mock-transfected or p5T-transfected culture controls (compare Fig. 4b and c) . Furthermore, the increased ratio of cut to uncut pol transcripts detected by DHPLC coincided with the time when there was a noticeable reduction of SIV p27 expression (compare Fig. 2a with Fig. 4c ).
To assess more thoroughly the packaging of wild-type SIV and p4T vector RNA, a limiting-dilution PCR was performed to quantify the amount of virus compared with p4T vector post-transfection to day 2 post-passage (day 16 following transfection). The number of vector copies per cell following transfection was 13?9 % of the number of virus copies per cell (Table 1) . Following serial passage of the transfected culture supernatants, the vector was detected at 14?2 % of the detectable virus ( 
DISCUSSION
Even in a very 'non-optimal' experimental setting and despite low transfection efficiencies (<0?3 vector copies per cell), these studies have described the passage of an anti-viral vector and suggest that mobilization is a feasible paradigm that needs further exploration. The antiretroviral effect observed in these studies, albeit relatively minimal, was retained with the passage of the anti-SIV vector p4T. However, there did appear to be a loss of efficiency with passage, as differences in virus replication in cultures infected with supernatants were not significant and could not be detected upon a third passage (data not shown).
It is not clear why the vectors alone did not demonstrate a greater anti-viral effect, as vectors alone have been described to have anti-HIV properties due to TAR and/or RRE decoy effects as well as by competition for encapsidation of viral RNA (Corbeau & Wong-Staal, 1998; Mautino et al., 2001 ). This vector effect of reducing the spread of HIV-1 in cell culture has been estimated to reduce the amount of wild-type HIV-1 in particles by roughly sixfold, thus ultimately leading to reduced particle infectivity and vector mobilization to target cells (Bukovsky et al., 1999; Corbeau & Wong-Staal, 1998) . However, the experiments described here only assessed p27 production in the nonribozyme (p5T) or antisense (p1T) and sense (p4T) *59-39Tat, PCR using 59 and 39 Tat primers specific for SIV. The limit of detection for this assay was 9?1 copies ml 21 in a 50 ml PCR.
D59Nef-39RT, PCR using the 59 Nef primer, which is SIV-specific, and the 39 Antisense RT-specific primer, which is specific to p4T. The limit of detection for this assay was 1?28 copies ml 21 in a 50 ml PCR. (Dropulic et al., 1992) . (b, c) DHPLC quantification of the relative percentages of cut (330 bp product), uncut (370 bp product) and nef virus transcripts at day 4 (no significant reduction in p27; Fig. 2a ) (b) and day 9 post-transfection (a significant reduction in p27; Fig. 2a ) (c). Significant differences based on the mean of quadruplicate wells from duplicate starting transfected SIVmac251-infected cultures, as assessed by Student's t-test (P<0?05), were noted in the p4T sample on day 4 compared with day 9 (% nef and 330 bp).
ribozyme-containing vector-treated cultures and the actual packaging of non-viral RNA was not determined for these samples.
The concept of anti-viral vector propagation has been described previously with HIV-1-based systems (Buchschacher & Wong-Staal, 1992; Bukovsky et al., 1999; Evans & Garcia, 2000; Klimatcheva et al., 2001) and was studied here with SIVmac. The data presented here provide a demonstration and quantification of a mobilization-competent anti-SIV vector that can be packaged and passaged along with the wild-type virus. These data indicate that it is possible to derive an anti-SIV gene therapy vector that exploits the virus machinery of infected cells to express a ribozyme targeting the wild-type virus and not the vector, and that the vector can compete with and be spread in a fashion similar to the wild-type virus, potentially introducing the therapeutic agent to many virus reservoirs. Interestingly, the noted early reduction in SIV p27 was not retained following serial passage, possibly due to the dissimilar rate of increase in wild-type virus compared with vector or a recombination event between the vector and virus that rendered the vector-containing ribozyme defective. While recombination is a significant possibility, it has been noted that vector-virus recombination is greatest between intact Gag/Gag-Pol (Wu et al., 2001) . Indeed, Gag sequences were retained in the p4T vector and the wild-type virus. However, whether the reduction of virus replication induced by p4T or a similar vector could be maintained within an in vivo setting in the presence of anti-retroviral therapy or following enhanced transduction utilizing a viral-based vector system (Mangeot et al., 2000) remains to be determined. Speculation through the interpretation of HIV-1 virus infection models has indicated that even small reductions in viral load of 2 % per replication cycle could prove significant (Coffin, 1995 (Coffin, , 1996 . More recently, molecular models of vector-virus interactions have indicated that if the vector is in~100-fold excess of the viral mRNA, a therapeutic virus set point equivalent to HAART could be achieved (Weinberger et al., 2003) . In these studies, vector p4T was shown to make up 13?9 % of the virus pool at day 2 post-serial passage and up to 17 % of the virus pool at day 14 post-serial passage. Whether these ratios could be increased by first transfecting/transducing target cells followed by virus infection or alternatively simply increasing overall transfection efficiency remains to be determined. Overall, the findings presented here indicate a need for further study of ribozyme stability and the development of vectors that are both inhibitory and capable of mobilization. These preliminary data should provide a premise to design more optimal mobilization-competent anti-SIV vectors that can be tested in the primate model.
